Melanoma — An Unlikely Poster Child for Personalized Cancer Therapy

摘要: Personalized medicine has long been a mainstay of the treatment localized melanoma, involving surgical decisions that are individualized on basis measured differences as small 0.01 mm, well other biomarkers metastatic potential, such presence ulceration or mitoses.1 Once melanoma spreads beyond regional nodes, however, lack validated molecular targets hampers efforts to individualize therapy. In this issue Journal, Flaherty and coworkers2 provide clinical proof mutations in gene encoding serine–threonine protein kinase B-RAF (BRAF) bona fide therapeutic melanoma. A remarkable . . .